ADVFN19d
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit the Company's website at ...
Benzinga.com21d
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars
Perspective Therapeutics reports no dose-limiting toxicities or severe adverse events in Phase 1/2a trial of [212Pb]VMT-α-NET. Anti-tumor activity observed: 1 confirmed response (17 weeks), 2 ...
ADVFN22d
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit the Company's website at ...
Eagle-Tribune22d
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
The Bakersfield Californian24d
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO ...
The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)” will be presented as a part of ...